Analisis Keuangan Saham RVMDW - Revolution Medicines, Inc.

Gambaran Umum

Revolution Medicines, Inc., based in the United States, operates within the biotechnology industry, specifically focusing on developing novel therapies to inhibit frontier cancer targets within notorious cancer pathways. The company's innovative platform is designed to generate small molecules that are tailored to counter elusive, high-value RAS(ON) and mTOR pathway targets. Key projects include advancing a diverse pipeline of drugs aimed at multi-faceted anti-tumor activities. This includes efforts targeting specific mutations and dependencies in RAS and mTOR signaling networks, critical drivers of cancer cells' growth and survival. Revolution Medicines' strategic approach combines deep scientific and clinical development expertise to address the complex challenges presented by these cancer biology areas.

Skor Kualitas, Nilai, dan Momentum

Kartu ini menunjukkan skor Kualitas, Nilai, dan Momentum untuk perusahaan tersebut.

Kualitas

The QualityScore is a proprietary scoring model that identifies high quality companies, based on cash generating efficiencies.

Nilai

Model penilaian eksklusif yang memberi peringkat pada perusahaan berdasarkan valuasi relatifnya. Skor berkisar antara 0 hingga 100, dengan 100 sebagai yang paling diremehkan nilainya.

Momentum

Proprietary scoring model that ranks companies on their six-month momentum.

Sentimen Dana

Skor Sentimen Dana (sebelumnya dikenal sebagai Skor Kepemilikan) adalah model kuantitatif eksklusif yang memberi peringkat pada perusahaan berdasarkan tingkat akumulasi kepemilikan.

QVM

The QVM Score is a proprietary scoring model that combines Quality, Value, and Momentum into a single metric that ranks companies from 0 to 100.

Laporan Laba Rugi: Pendapatan, Laba Operasional, Laba Bersih

Nilai operating income untuk Revolution Medicines, Inc. - Equity Warrant per 2025 Jun 30 adalah -897.50 MM.
Nilai net income untuk Revolution Medicines, Inc. - Equity Warrant per 2025 Jun 30 adalah -812.06 MM.

Period End (TTM)	Revenue (MM)	Operating Income (MM)	Net Income (MM)
2025-06-30		-897.50	-812.06
2025-03-31		-789.42	-697.51
2024-12-31		-689.52	-600.09
2024-09-30	0.74	-627.70	-567.06
2024-06-30	0.74	-575.23	-519.21
2024-03-31	4.57	-527.39	-484.27
2023-12-31	11.58	-461.69	-436.37
2023-09-30	26.17	-368.91	-331.34
2023-06-30	29.52	-322.19	-296.23
2023-03-31	34.82	-275.49	-259.16
2022-12-31	35.38	-258.28	-248.71
2022-09-30	29.51	-249.49	-244.87
2022-06-30	27.25	-226.12	-224.49
2022-03-31	26.84	-208.56	-207.56
2021-12-31	29.39	-188.01	-187.09
2021-09-30	28.68	-169.18	-168.62
2021-06-30	40.24	-143.56	-142.90
2021-03-31	41.57	-127.01	-125.82
2020-12-31	42.98	-110.70	-108.16
2020-09-30	46.32	-96.18	-88.55
2020-06-30

Laporan Laba Rugi: EPS

Period End (TTM)	Earnings Per Share Basic	Earnings Per Share Diluted
2025-06-30
2025-03-31
2024-12-31	-3.58
2024-09-30	-3.55	-3.55
2024-06-30	-3.58	-3.58
2024-03-31	-3.71	-3.71
2023-12-31	-3.86
2023-09-30	-3.31	-3.31
2023-06-30	-3.15	-3.15
2023-03-31	-3.02	-3.02
2022-12-31	-3.08
2022-09-30	-3.19	-3.19
2022-06-30	-3.04	-3.04
2022-03-31	-2.81	-2.81
2021-12-31	-2.57
2021-09-30	-2.38	-2.38
2021-06-30	-2.08	-2.08
2021-03-31	-1.93	-1.93
2020-12-31	-2.01
2020-09-30	-2.44	-2.44
2020-06-30	-3.62	-3.62

Arus Kas: Operasi, Investasi, Pendanaan

Nilai cash from operating activities untuk Revolution Medicines, Inc. - Equity Warrant per 2025 Jun 30 adalah -684.90 MM.
Nilai cash from investing activities untuk Revolution Medicines, Inc. - Equity Warrant per 2025 Jun 30 adalah -396.05 MM.
Nilai kas dari aktivitas pendanaan untuk Revolution Medicines, Inc. - Equity Warrant per 2025 Jun 30 adalah 1,208.56 MM.

Period End (TTM)	Cash From Operating Activities (MM)	Cash From Investing Activities (MM)	Cash From Financing Activities (MM)
2025-06-30	-684.90	-396.05	1,208.56
2025-03-31	-591.31	-322.38	959.48
2024-12-31	-557.44	-554.39	959.41
2024-09-30	-539.71	-541.89	924.96
2024-06-30	-509.79	-443.07	848.68
2024-03-31	-448.74	-594.56	905.80
2023-12-31	-350.57	-342.60	1,229.20
2023-09-30	-291.80	30.70	441.21
2023-06-30	-243.04	-170.09	688.53
2023-03-31	-231.63	-64.14	625.33
2022-12-31	-224.40	-24.12	301.43
2022-09-30	-201.88	-8.48	260.80
2022-06-30	-186.73	84.78	12.78
2022-03-31	-165.09	-100.40	12.22
2021-12-31	-147.18	-142.12	294.18
2021-09-30	-132.95	-87.70	284.94
2021-06-30	-123.38	-158.49	453.50
2021-03-31	-109.29	-172.21	451.30
2020-12-31	-100.06	-234.23	422.78
2020-09-30	-86.68	-289.16	419.76
2020-06-30

Metrik Penilaian: PE, PriceToBook, PriceToTBV

P/Book: The current closing price divided by the book value per share.

P/TBV: The current price divided by the tangible book value per share.

Period End (TTM)	p/e	P/Book	P/TBV
2025-06-30
2025-03-31
2024-12-31
2024-09-30
2024-06-30
2024-03-31
2023-12-31
2023-09-30
2023-06-30
2023-03-31
2022-12-31
2022-09-30
2022-06-30
2022-03-31
2021-12-31
2021-09-30
2021-06-30
2021-03-31
2020-12-31
2020-09-30
2020-06-30

Metrik Penilaian: EBitToEv, EBit3YrAvgToEv

Period End (TTM)	EBIT/EV	EBIT (3y)/EV
2025-06-30
2025-03-31
2024-12-31
2024-09-30
2024-06-30
2024-03-31
2023-12-31
2023-09-30
2023-06-30
2023-03-31
2022-12-31
2022-09-30
2022-06-30
2022-03-31
2021-12-31
2021-09-30
2021-06-30
2021-03-31
2020-12-31
2020-09-30
2020-06-30

Efektivitas Manajemen

roa untuk Revolution Medicines, Inc. - Equity Warrant pada 2025 Jun 30 adalah -0.39.
roe untuk Revolution Medicines, Inc. - Equity Warrant pada 2025 Jun 30 adalah -0.43.
roic untuk Revolution Medicines, Inc. - Equity Warrant pada 2025 Jun 30 adalah -0.32.
croic untuk Revolution Medicines, Inc. - Equity Warrant pada 2025 Jun 30 adalah 0.02.
ocroic untuk Revolution Medicines, Inc. - Equity Warrant pada 2025 Jun 30 adalah -0.27.

Period End (TTM)	ROA	ROE	ROIC (Tingkat Pengembalian Investasi Modal)	CROIC	OCROIC
2025-06-30	-0.39	-0.43	-0.32	0.02	-0.27
2025-03-31	-0.37	-0.40	-0.32	0.02	-0.27
2024-12-31	-0.29	-0.33	-0.25	-0.06	-0.23
2024-09-30	-0.58	-0.68	-0.34	-0.09	-0.33
2024-06-30	-0.45	-0.51	-0.27	-0.08	-0.25
2024-03-31	-0.54	-0.64	-0.23	0.28	-0.18
2023-12-31	-0.40	-0.49	-0.37	0.20	-0.32
2023-09-30	-0.47	-0.59	-0.30	0.28	-0.24
2023-06-30	-0.47	-0.59	-0.30	0.28	-0.24
2023-03-31	-0.38	-0.47	-0.26	0.32	-0.23
2022-12-31	-0.33	-0.38	-0.33	0.07	-0.27
2022-09-30	-0.33	-0.38	-0.33	0.07	-0.27
2022-06-30	-0.29	-0.33	-0.40	-0.16	-0.33
2022-03-31	-0.26	-0.29	-0.34	-0.41	-0.27
2021-12-31	-0.33	-0.39	-0.28	0.01	-0.22
2021-09-30	-0.28	-0.33	-0.25	0.10	-0.20
2021-06-30	-0.31	-0.40	-0.20	0.24	-0.17
2021-03-31	-0.28	-0.33	-0.17	0.23	-0.14
2020-12-31	-0.49	-0.71	-0.21	0.17	-0.20
2020-09-30	-0.38	-0.53	-0.16	0.08	-0.16
2020-06-30	-0.43	-0.77	-0.19	-0.15	-0.19

Gross Margins

Margin Kotor: The Gross Margin is the ratio of revenue left after substracting the Cost of Goods Sold. It is calculated as 1.0 - (Revenue - COGS ) / Revenue.

Margin Keuntungan Bersih: Margin Bersih (juga dikenal sebagai Margin Keuntungan) adalah rasio pendapatan yang tersisa setelah dikurangi Pendapatan Bersih. Perhitungannya adalah Pendapatan Bersih / Pendapatan.

Margin Operasi: Margin Operasi adalah rasio pendapatan yang tersisa setelah dikurangi Pendapatan Operasi. Perhitungannya adalah Pendapatan Operasi / Pendapatan.

Period End (TTM)	Margin Kotor	Margin Keuntungan Bersih	Margin Operasi
2025-06-30
2025-03-31	-915.38	-940.04	-1,063.92
2024-12-31	-797.15	-808.75	-929.28
2024-09-30	-727.72	-764.23	-845.95
2024-06-30	-99.81	-106.06	-115.50
2024-03-31	-34.51	-37.68	-39.87
2023-12-31	-12.02	-12.66	-14.10
2023-09-30	-9.25	-10.03	-10.91
2023-06-30	-9.25	-10.03	-10.91
2023-03-31	-6.63	-7.44	-7.91
2022-12-31	-7.15	-8.30	-8.45
2022-09-30	-7.15	-8.30	-8.45
2022-06-30	-6.99	-8.24	-8.30
2022-03-31	-6.55	-7.73	-7.77
2021-12-31	-5.36	-6.37	-6.40
2021-09-30	-4.94	-5.88	-5.90
2021-06-30	-2.94	-3.55	-3.57
2021-03-31	-2.50	-3.03	-3.06
2020-12-31	-2.08	-2.52	-2.58
2020-09-30	-1.65	-1.91	-2.08
2020-06-30	-1.40	-1.61	-1.78

Analisis Keuangan Saham RVMDW - Revolution Medicines, Inc. - Equity Warrant (NasdaqGS) Stock